Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants

The emergence of increasingly immunoevasive SARS-CoV-2 variants emphasizes the need for prophylactic strategies to complement vaccination in fighting the COVID-19 pandemic. Intranasal administration of neutralizing antibodies has shown encouraging protective potential but there remains a need for SA...

Descripción completa

Detalles Bibliográficos
Autores principales: Mäkelä, Anna R., Uğurlu, Hasan, Hannula, Liina, Kant, Ravi, Salminen, Petja, Fagerlund, Riku, Mäki, Sanna, Haveri, Anu, Strandin, Tomas, Kareinen, Lauri, Hepojoki, Jussi, Kuivanen, Suvi, Levanov, Lev, Pasternack, Arja, Naves, Rauno A., Ritvos, Olli, Österlund, Pamela, Sironen, Tarja, Vapalahti, Olli, Kipar, Anja, Huiskonen, Juha T., Rissanen, Ilona, Saksela, Kalle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037368/
https://www.ncbi.nlm.nih.gov/pubmed/36964125
http://dx.doi.org/10.1038/s41467-023-37290-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037368/
https://www.ncbi.nlm.nih.gov/pubmed/36964125
http://dx.doi.org/10.1038/s41467-023-37290-6

Ejemplares similares